1. Home
  2. SANG vs LCTX Comparison

SANG vs LCTX Comparison

Compare SANG & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sangoma Technologies Corporation

SANG

Sangoma Technologies Corporation

N/A

Current Price

$5.00

Market Cap

170.0M

Sector

Technology

ML Signal

N/A

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.67

Market Cap

407.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SANG
LCTX
Founded
1984
1990
Country
Canada
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
170.0M
407.7M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
SANG
LCTX
Price
$5.00
$1.67
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$4.25
AVG Volume (30 Days)
3.5K
1.2M
Earning Date
02-04-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$227,360,000.00
$10,816,000.00
Revenue This Year
N/A
$6.32
Revenue Next Year
$4.59
$124.49
P/E Ratio
N/A
N/A
Revenue Growth
N/A
24.05
52 Week Low
$4.08
$0.37
52 Week High
$7.99
$2.09

Technical Indicators

Market Signals
Indicator
SANG
LCTX
Relative Strength Index (RSI) 45.46 46.04
Support Level $4.86 $1.58
Resistance Level $5.08 $1.77
Average True Range (ATR) 0.13 0.08
MACD -0.03 -0.01
Stochastic Oscillator 32.52 32.65

Price Performance

Historical Comparison
SANG
LCTX

About SANG Sangoma Technologies Corporation

Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: